USPSTF released a draft recommendation statement on breast cancer screening; little has changed since the last statement in 2009.
The United States Preventive Services Task Force (USPSTF) posted their draft recommendation regarding breast cancer screening and is asking for public comment until May 18, 2015 at 8:00 PM EST.
Despite pressure from breast cancer screening proponents who want the recommendations to include annual mammography screening for women starting at age 40, the USPSTF guidelines largely mirror the 2009 recommendations of biennial screening for women ages 50-74.
The recommendations state that there is “adequate evidence that mammography screening reduces breast cancer mortality in women ages 40-74 years.” Women ages 40-49 benefit the least from mammography screening, and women ages 60-69 benefit the most, according to the rationale. The USPSTF also cited “adequate evidence that screening for breast cancer for mammography results in harms for women ages 50-74 years.” The most important harm, according to the rationale, is the “diagnosis and treatment of noninvasive and invasive breast cancer that would otherwise not have become a threat to a woman’s health, or even apparent, during her lifetime (i.e., overdiagnosis and overtreatment.” The rationale cited psychological harms and unnecessary invasive testing that accompany overdiagnosis and overtreatment.
The USPSTF was unable to come to a conclusion about the balance of benefits and harms of tomosynthesis as a primary screening modality for breast cancer. They similarly cited no adequate evidence for benefits and harms of adjunctive screening for breast cancer using ultrasound, MRI, tomosynthesis, or other modalities in women identified to have dense breasts or a negative screening mammogram.
“While there is some information about the accuracy of these modalities, there is no information on the effects of their use on health outcomes, such as breast cancer incidence, mortality, or overdiagnosis rates,” the recommendation states.
This is only a draft of the recommendations. Public input will be accepted until May 18, 2015 at 8:00 PM EST. A final recommendation will be developed after careful consideration of the feedback received, according to the USPSTF. Make sure to voice your concerns during this period. Read the full recommendation here.
Summary of the Guidelines:
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
Is the Kaiser Score More Effective than BI-RADS for Assessing Contrast-Enhanced Mammography and MRI?
October 14th 2024For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.
FDA Clears New Features in AI-Powered Mammography Software Suite
October 11th 2024Therapixel’s MammoScreen suite has received 510(k) FDA clearances for a breast density assessment feature and updated software that includes automated pre-reporting, which reportedly expedites reporting of mammography findings.